Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Compass Therapeutics Inc (CMPX)

Compass Therapeutics Inc (CMPX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Mon Aug 1, 2022

Phase 2/3 trial of CTX-009 (DLL4 X VEGF-A bispecific) and paclitaxel in biliary tract cancer (BTC) anticipated to begin in the United States in Q3 2022A...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference Globe Newswire - Mon May 23, 2022

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress Globe Newswire - Mon May 9, 2022

The FDA cleared the investigational new drug application for CTX-009 (DLL4 X VEGF-A bispecific) in January allowing the Company to expand the ongoing Phase...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009 Globe Newswire - Tue May 3, 2022

Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting Globe Newswire - Fri Apr 8, 2022

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans Globe Newswire - Wed Mar 30, 2022

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Globe Newswire - Mon Mar 21, 2022

Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A) Globe Newswire - Thu Jan 20, 2022

BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire - Fri Jan 7, 2022

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D.,...

CMPX : 1.4800 (-2.63%)
Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference Business Wire - Mon Nov 22, 2021

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, MD, PhD, Co-founder,...

CMPX : 1.4800 (-2.63%)

Barchart Exclusives

1 Stock to Profit from the U.S. Infrastructure Spending Bonanza Barchart - 11 minutes ago
The poor state of U.S. infrastructure is why the government has allocated trillions of dollars in federal funding towards upgrading it. While this spending is good for the country, it will be great for the companies that supply construction materials - like aggregates and concrete giant Vulcan Materials. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot